CHI3L1 and ovarian carcinoma: In 2018, Boisen and colleagues reported an improvement in patients’ outcome—particularly for progression-free survival (PFS)—after bevacizumab treatment for patients with low baseline YKL40 plasma levels [49]; similar results were observed in ovarian cancer patients [66].